Ostarine (MK-2866) 10 mg – 100 Capsules

Biochem Ostarine (MK-2866) 10 mg – 100 Capsules | Selective Androgen Receptor Modulator (SARM)

Biochem Ostarine (MK-2866) 10 mg – 100 Capsules is an oral capsule product containing ostarine, also known as enobosarm, MK-2866, GTx-024, or S-22, a synthetic nonsteroidal selective androgen receptor modulator (SARM) developed for investigation of androgen receptor activity in skeletal muscle and bone.

This product contains 10 mg of ostarine per capsule, with 100 capsules per package, representing 1,000 mg (1 gram) of ostarine per package, based on the stated formulation.

Ostarine belongs to a class of compounds known as selective androgen receptor modulators. These compounds interact with androgen receptors and influence biological pathways associated with muscle metabolism, bone physiology, and androgen-responsive gene expression.

Androgen receptors are intracellular nuclear receptors that regulate cellular responses to androgens, including testosterone and dihydrotestosterone.

Unlike traditional anabolic-androgenic steroids, ostarine does not possess the classical steroidal chemical structure found in testosterone-derived compounds.

Instead, ostarine is a synthetic nonsteroidal molecule designed to interact with androgen receptors and influence receptor-mediated transcriptional activity.

Ostarine was developed as a potential therapeutic compound for conditions involving loss of skeletal muscle, reduced physical function, and altered body composition.

Clinical development has included investigations involving older adults, patients with cancer-associated muscle loss, and other populations experiencing changes in muscle mass or physical performance.

Some controlled human studies reported increases in lean body mass following exposure to enobosarm.

However, increases in lean body mass have not consistently translated into clinically meaningful improvements in physical function, strength, or long-term health outcomes.

Ostarine has also been investigated in oncology-related clinical development programs, including research involving androgen receptor signaling in selected cancers.

These investigations do not establish ostarine as an approved treatment for cancer, muscle wasting, osteoporosis, sarcopenia, or other medical conditions.

Although ostarine is frequently discussed in bodybuilding and athletic performance contexts, adequate clinical evidence does not establish that it safely improves muscle growth, endurance, recovery, or athletic performance in healthy individuals.

Ostarine is not testosterone, recombinant growth hormone, a peptide hormone, or a conventional anabolic-androgenic steroid.

Its primary molecular mechanism involves androgen receptor modulation, distinguishing it from ibutamoren (MK-677), which acts through the ghrelin receptor, and cardarine (GW-501516), which acts primarily through PPARδ.

Despite its intended tissue-selective properties, ostarine may produce systemic effects involving reproductive hormone regulation, liver function, lipid metabolism, and cardiovascular physiology.

Liver injury associated with SARM products, including products identified as ostarine, has been reported. The actual ingredient identity and purity of unverified commercial products can complicate interpretation of individual adverse-event reports.

Ostarine is prohibited in competitive sport under World Anti-Doping Agency rules.

The Biochem brand name does not independently establish pharmaceutical approval, manufacturing quality, analytical purity, or clinical suitability.

1. Selectively Interacts With Androgen Receptors

Ostarine is a synthetic nonsteroidal compound developed to bind to androgen receptors.

Androgen receptors are nuclear proteins that regulate gene expression in response to androgenic signaling.

Following ligand binding, androgen receptors undergo conformational changes that influence interactions with transcriptional regulatory proteins.

These interactions affect the expression of androgen-responsive genes.

The resulting biological effects depend on tissue characteristics, receptor expression, and the pharmacological properties of the compound.

2. Was Developed for Tissue-Selective Androgen Receptor Activity

The development of SARMs was motivated by the possibility of influencing selected androgen-responsive tissues without reproducing every effect associated with traditional anabolic-androgenic steroids.

Ostarine was investigated particularly for its potential effects on skeletal muscle and musculoskeletal physiology.

However, tissue selectivity does not mean that ostarine acts exclusively in muscle or bone.

Systemic endocrine, metabolic, hepatic, and cardiovascular effects remain possible.

3. Has Been Investigated in Lean Body Mass Research

Androgen receptor signaling contributes to skeletal muscle protein metabolism and tissue maintenance.

Controlled clinical investigations have examined whether ostarine can influence lean body mass in populations experiencing muscle loss or changes in physical function.

Some studies reported increases in lean body mass.

However, changes in lean body mass do not necessarily establish improvements in muscle strength, mobility, endurance, or other functional outcomes.

These findings do not justify claims of proven muscle-building effectiveness or safety in healthy individuals.

4. Has Been Investigated in Cancer-Associated Muscle Loss

Ostarine underwent clinical investigation for conditions involving cancer-associated muscle wasting.

The objective of these studies was to evaluate whether androgen receptor modulation could influence lean body mass and functional measurements.

Although certain body composition outcomes showed changes, pivotal clinical development did not establish the functional benefits necessary to support an approved treatment for cancer-associated muscle wasting.

Ostarine should not be represented as an established treatment for cachexia or cancer-related muscle loss.

5. Differs Chemically From Anabolic-Androgenic Steroids

Ostarine does not contain the classical steroid nucleus characteristic of testosterone and many anabolic-androgenic steroids.

Nevertheless, it interacts with androgen receptors and can influence endocrine physiology.

A nonsteroidal chemical structure does not establish freedom from hormonal suppression, liver injury, lipid abnormalities, or other androgen-related adverse effects.

6. Has Been Evaluated in Human Clinical and Pharmacokinetic Studies

Ostarine has undergone human clinical investigation, including studies examining oral exposure, body composition, endocrine effects, and safety measurements.

These studies provide evidence that ostarine is orally active and can influence androgen-responsive physiological processes.

However, published clinical findings do not independently establish the absorption, exposure, or elimination characteristics of a particular commercial capsule formulation.

The exact pharmacokinetic profile of Biochem Ostarine 10 mg has not been independently verified.

7. Has Important Hepatic, Endocrine, and Long-Term Safety Concerns

Ostarine and other SARMs have been associated with changes in endogenous hormone regulation, lipid measurements, and liver-related laboratory values.

Reports of liver injury associated with products identified as ostarine raise additional concerns.

Potential risks include suppression of reproductive hormone signaling, adverse cholesterol changes, liver injury, and uncertain cardiovascular effects.

Long-term human safety data are insufficient to determine the frequency, severity, or reversibility of many potential adverse effects.

Ostarine has no established approved therapeutic indication for muscle growth, athletic performance, recovery, osteoporosis, sarcopenia, cancer-associated muscle loss, or hormone replacement.

The 10 mg capsule strength describes the product presentation and does not establish a medically validated or safe human dose.

Step 1 – Oral Capsule Administration and Absorption

Ostarine is an orally active nonsteroidal androgen receptor modulator.

Following oral administration, the compound can be absorbed through the gastrointestinal tract and enter systemic circulation.

The absorption characteristics of this specific Biochem capsule formulation have not been independently established.

Step 2 – Distribution to Androgen-Responsive Tissues

Following absorption, ostarine may distribute to tissues containing androgen receptors.

Potential target tissues include skeletal muscle, bone, and other androgen-responsive organs.

The tissue distribution of the requested Biochem formulation has not been independently established.

Step 3 – Interaction With Androgen Receptors

Ostarine binds to androgen receptors and influences receptor-associated signaling.

The resulting receptor conformation can affect interactions with transcriptional regulatory proteins.

These interactions participate in the regulation of androgen-responsive gene expression.

Step 4 – Modulation of Gene Transcription

Androgen receptor signaling can influence genes involved in skeletal muscle metabolism, tissue maintenance, and other physiological processes.

The biological consequences depend on tissue characteristics and individual endocrine conditions.

Preclinical observations and changes in clinical biomarkers cannot independently establish long-term therapeutic benefits.

Step 5 – Metabolism and Elimination

Following systemic exposure, ostarine undergoes metabolic processing and elimination.

Human pharmacokinetic research provides information about its systemic exposure and persistence.

However, the complete metabolic and elimination characteristics of this particular Biochem capsule formulation have not been independently verified.

The Biochem Ostarine 10 mg capsule presentation includes the following characteristics:

• Ostarine (MK-2866) as the stated active compound.
• Alternative names enobosarm, GTx-024, and S-22.
• 10 mg per capsule.
• 100 capsules per package.
• 1,000 mg total stated active ingredient content.
• Oral capsule presentation.
• Nonsteroidal chemical classification.
• Selective androgen receptor modulator classification.
• Androgen receptor-binding activity.
• Modulation of androgen-responsive gene transcription.
• Investigation of skeletal muscle physiology.
• Investigation of lean body mass changes.
• Controlled human clinical research.
• Clinical development involving cancer-associated muscle loss.
• Investigation of selected oncology-related applications.
• No established approved human therapeutic indication.
• No validated safe human dosing regimen.
• Reported body composition changes in selected clinical studies.
• No consistently demonstrated improvement in functional physical performance.
• Potential changes in endogenous reproductive hormone regulation.
• Potential adverse effects on cholesterol measurements.
• Reported liver injury associated with SARM products.
• Inadequately characterized long-term cardiovascular safety.
• No established clinical benefit for athletic performance.
• Prohibited status under WADA rules.
• Capsule excipients requiring confirmation.
• Identity, purity, and content uniformity requiring independent analytical verification.

The precise excipient composition, capsule appearance, manufacturing specifications, purity, and analytical content of Biochem Ostarine 10 mg have not been independently verified.

The stated package contains 100 capsules of 10 mg each, representing 1,000 mg total stated active ingredient.

This description does not establish regulatory authorization, clinical safety, or suitability for human administration.

United States

Biochem Ostarine 10mg, Biochem MK2866 10mg, Ostarine 10mg 100 capsules, MK2866 100 capsules, Ostarine United States, Ostarine selective androgen receptor modulator, MK2866 SARM compound, Enobosarm 10mg, Ostarine molecular formula, Ostarine chemical structure, MK2866 androgen receptor activity, Ostarine pharmacology, Ostarine clinical studies, MK2866 lean body mass research, Ostarine muscle physiology, Ostarine hormone effects, MK2866 safety concerns, Ostarine clinical evidence, Ostarine capsule specifications.

Canada

English: Biochem Ostarine 10mg Canada, MK2866 10mg Canada, Ostarine 100 capsules, Ostarine SARM, Enobosarm Canada, selective androgen receptor modulator, Ostarine properties, MK2866 pharmacology, Ostarine molecular structure, MK2866 androgen receptor, Ostarine clinical research, MK2866 lean body mass, Ostarine endocrine effects, MK2866 safety information, Ostarine clinical evidence.

French: Biochem Ostarine 10 mg Canada, MK2866 10 mg, Ostarine 100 capsules, Enobosarm, modulateur sélectif des récepteurs aux androgènes, propriétés de l'ostarine, pharmacologie du MK2866, récepteur aux androgènes, structure moléculaire, études cliniques, masse corporelle maigre, physiologie musculaire, effets endocriniens, risques hépatiques, informations de sécurité, données cliniques.

United Kingdom

Biochem Ostarine 10mg UK, Ostarine MK2866 UK, Ostarine 100 capsules, Enobosarm UK, selective androgen receptor modulator, MK2866 SARM, Ostarine pharmacology, Ostarine chemical structure, MK2866 androgen receptor binding, Ostarine clinical studies, Ostarine lean body mass research, MK2866 muscle physiology, Ostarine hormonal effects, MK2866 safety profile, Ostarine clinical evidence.

Germany

Biochem Ostarine 10 mg Deutschland, Ostarine MK2866, Ostarine 100 Kapseln, Enobosarm, selektiver Androgenrezeptormodulator, SARM Ostarine, Ostarine Eigenschaften, MK2866 Wirkungsmechanismus, Androgenrezeptor, Ostarine Molekülstruktur, klinische Studien, fettfreie Körpermasse, Muskelphysiologie, hormonelle Veränderungen, Leberrisiken, Sicherheitsinformationen.

France

Biochem Ostarine 10 mg France, Ostarine MK2866, Ostarine 100 gélules, Enobosarm, modulateur sélectif des récepteurs aux androgènes, SARM Ostarine, propriétés de l'ostarine, mécanisme d'action du MK2866, récepteur aux androgènes, structure moléculaire, études cliniques, masse maigre, physiologie musculaire, effets hormonaux, risques hépatiques, informations de sécurité.

Spain

Biochem Ostarine 10 mg España, Ostarine MK2866, Ostarine 100 cápsulas, Enobosarm, modulador selectivo del receptor de andrógenos, SARM Ostarine, propiedades de la ostarina, mecanismo de acción del MK2866, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, riesgos hepáticos, información de seguridad.

Italy

Biochem Ostarine 10 mg Italia, Ostarine MK2866, Ostarine 100 capsule, Enobosarm, modulatore selettivo del recettore degli androgeni, SARM Ostarine, proprietà dell'ostarina, meccanismo d'azione MK2866, recettore degli androgeni, struttura molecolare, studi clinici, massa magra, fisiologia muscolare, effetti ormonali, rischi epatici, informazioni di sicurezza.

Portugal

Biochem Ostarine 10 mg Portugal, Ostarine MK2866, Ostarine 100 cápsulas, Enobosarm, modulador seletivo dos recetores de androgénios, SARM Ostarine, propriedades da ostarina, mecanismo de ação do MK2866, recetor de androgénios, estrutura molecular, estudos clínicos, massa corporal magra, fisiologia muscular, efeitos hormonais, riscos hepáticos, informações de segurança.

Netherlands

Biochem Ostarine 10 mg Nederland, Ostarine MK2866, Ostarine 100 capsules, Enobosarm, selectieve androgeenreceptormodulator, SARM Ostarine, eigenschappen van ostarine, werkingsmechanisme MK2866, androgeenreceptor, moleculaire structuur, klinische studies, vetvrije massa, spierfysiologie, hormonale effecten, leverrisico's, veiligheidsinformatie.

Belgium

Biochem Ostarine 10 mg België, Ostarine 10 mg Belgique, Ostarine MK2866, Ostarine 100 capsules, Enobosarm, selectieve androgeenreceptormodulator, modulateur sélectif des récepteurs aux androgènes, SARM Ostarine, eigenschappen van ostarine, propriétés de l'ostarine, androgeenreceptor, récepteur aux androgènes, klinische studies, études cliniques, hormonale effecten, effets hormonaux, veiligheidsinformatie.

Switzerland

Biochem Ostarine 10 mg Schweiz, Ostarine 10 mg Suisse, Ostarine MK2866, Ostarine 100 Kapseln, Ostarine 100 gélules, Enobosarm, selektiver Androgenrezeptormodulator, modulateur sélectif des récepteurs aux androgènes, SARM Ostarine, Androgenrezeptor, récepteur aux androgènes, klinische Studien, études cliniques, hormonelle Veränderungen, effets hormonaux, Sicherheitsinformationen.

Austria

Biochem Ostarine 10 mg Österreich, Ostarine MK2866, Ostarine 100 Kapseln, Enobosarm, selektiver Androgenrezeptormodulator, SARM Ostarine, Ostarine Eigenschaften, MK2866 Wirkungsmechanismus, Androgenrezeptor, Molekülstruktur, klinische Forschung, fettfreie Körpermasse, Muskelphysiologie, hormonelle Veränderungen, Leberrisiken, Sicherheitsinformationen.

Sweden

Biochem Ostarine 10 mg Sverige, Ostarine MK2866, Ostarine 100 kapslar, Enobosarm, selektiv androgenreceptormodulator, SARM Ostarine, ostarine egenskaper, MK2866 verkningsmekanism, androgenreceptor, molekylstruktur, kliniska studier, fettfri kroppsmassa, muskelfysiologi, hormonella effekter, leverrisker, säkerhetsinformation.

Norway

Biochem Ostarine 10 mg Norge, Ostarine MK2866, Ostarine 100 kapsler, Enobosarm, selektiv androgenreseptormodulator, SARM Ostarine, ostarine egenskaper, MK2866 virkningsmekanisme, androgenreseptor, molekylstruktur, kliniske studier, fettfri kroppsmasse, muskelfysiologi, hormonelle effekter, leverrisiko, sikkerhetsinformasjon.

Denmark

Biochem Ostarine 10 mg Danmark, Ostarine MK2866, Ostarine 100 kapsler, Enobosarm, selektiv androgenreceptormodulator, SARM Ostarine, ostarine egenskaber, MK2866 virkningsmekanisme, androgenreceptor, molekylstruktur, kliniske studier, fedtfri kropsmasse, muskelfysiologi, hormonelle effekter, leverrisici, sikkerhedsinformation.

Finland

Biochem Ostarine 10 mg Suomi, Ostarine MK2866, Ostarine 100 kapselia, Enobosarm, selektiivinen androgeenireseptorin muuntelija, SARM Ostarine, ostariinin ominaisuudet, MK2866 vaikutusmekanismi, androgeenireseptori, molekyylirakenne, kliiniset tutkimukset, rasvaton kehonmassa, lihasfysiologia, hormonaaliset vaikutukset, maksariskit, turvallisuustiedot.

Poland

Biochem Ostarine 10 mg Polska, Ostarine MK2866, Ostarine 100 kapsułek, Enobosarm, selektywny modulator receptora androgenowego, SARM Ostarine, właściwości ostaryny, mechanizm działania MK2866, receptor androgenowy, struktura molekularna, badania kliniczne, beztłuszczowa masa ciała, fizjologia mięśni, zmiany hormonalne, ryzyko uszkodzenia wątroby, informacje o bezpieczeństwie.

Czech Republic

Biochem Ostarine 10 mg Česko, Ostarine MK2866, Ostarine 100 kapslí, Enobosarm, selektivní modulátor androgenového receptoru, SARM Ostarine, vlastnosti ostarinu, mechanismus účinku MK2866, androgenový receptor, molekulární struktura, klinické studie, beztuková tělesná hmota, svalová fyziologie, hormonální účinky, rizika poškození jater, bezpečnostní informace.

Romania

Biochem Ostarine 10 mg România, Ostarine MK2866, Ostarine 100 capsule, Enobosarm, modulator selectiv al receptorilor androgenici, SARM Ostarine, proprietăți ostarină, mecanism de acțiune MK2866, receptor androgenic, structură moleculară, studii clinice, masă corporală slabă, fiziologie musculară, efecte hormonale, riscuri hepatice, informații de siguranță.

Greece

Biochem Ostarine 10 mg Ελλάδα, οσταρίνη MK2866, Ostarine 100 κάψουλες, Enobosarm, εκλεκτικός τροποποιητής υποδοχέων ανδρογόνων, SARM Ostarine, ιδιότητες οσταρίνης, μηχανισμός δράσης MK2866, υποδοχέας ανδρογόνων, μοριακή δομή, κλινικές μελέτες, άλιπη σωματική μάζα, μυϊκή φυσιολογία, ορμονικές επιδράσεις, ηπατικοί κίνδυνοι, πληροφορίες ασφάλειας.

Ireland

Biochem Ostarine 10mg Ireland, Ostarine MK2866 Ireland, Ostarine 100 capsules, Enobosarm Ireland, selective androgen receptor modulator, MK2866 SARM, Ostarine pharmacology, Ostarine molecular structure, MK2866 androgen receptor activity, Ostarine clinical studies, Ostarine lean body mass research, MK2866 muscle physiology, Ostarine hormonal effects, MK2866 safety information, limited long-term human evidence.

Colombia

Biochem Ostarine 10 mg Colombia, Ostarine MK2866 Colombia, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM ostarina, propiedades de la ostarina, cómo funciona el MK2866, farmacología de la ostarina, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, información de seguridad, evidencia clínica.

Argentina

Biochem Ostarine 10 mg Argentina, Ostarine MK2866 Argentina, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM ostarina, propiedades de la ostarina, qué es el MK2866, mecanismo de acción de la ostarina, receptor androgénico, estructura molecular, estudios clínicos, masa magra, fisiología muscular, cambios hormonales, información de seguridad.

México

Biochem Ostarine 10 mg México, Ostarine MK2866 México, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM Ostarine, propiedades de la ostarina, para qué se investigó el MK2866, cómo funciona la ostarina, farmacología del MK2866, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, efectos hormonales, evidencia clínica.

Perú

Biochem Ostarine 10 mg Perú, Ostarine MK2866 Perú, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM ostarina, propiedades de la ostarina, mecanismo de acción del MK2866, farmacología de la ostarina, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, información de seguridad.

Venezuela

Biochem Ostarine 10 mg Venezuela, Ostarine MK2866 Venezuela, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM Ostarine, propiedades de la ostarina, qué es el MK2866, cómo actúa la ostarina, farmacología del MK2866, receptor de andrógenos, estructura molecular, estudios clínicos, masa magra, efectos hormonales, evidencia clínica.

Ecuador

Biochem Ostarine 10 mg Ecuador, Ostarine MK2866 Ecuador, Ostarine 100 cápsulas, ostarina 10 mg, enobosarm, modulador selectivo del receptor de andrógenos, SARM Ostarine, propiedades de la ostarina, cómo funciona el MK2866, farmacología de la ostarina, mecanismo de acción, receptor de andrógenos, estructura molecular, estudios clínicos, masa corporal magra, fisiología muscular, efectos hormonales, información de seguridad.

Biochem Ostarine (MK-2866) 10mg | 100 Capsules | Selective Androgen Receptor Modulator

Learn about Biochem Ostarine MK-2866 10mg, 100 capsules. This product contains ostarine (enobosarm), a nonsteroidal selective androgen receptor modulator studied for lean body mass and muscle physiology, with important hepatic and endocrine safety concerns and no established approved therapeutic use.

Biochem Ostarine (MK-2866) 10mg | 100 Cápsulas | Modulador Selectivo del Receptor de Andrógenos

Conoce Biochem Ostarine MK-2866 10mg, 100 cápsulas. Este producto contiene ostarina (enobosarm), un modulador selectivo no esteroideo del receptor de andrógenos estudiado por sus efectos sobre la masa corporal magra y la fisiología muscular, con importantes riesgos hepáticos y endocrinos y sin uso terapéutico aprobado establecido.

biochem-ostarine-mk2866-10mg-100-capsules

biochem-ostarine-mk2866-10mg-100-capsulas

Biochem Ostarine MK-2866 10mg, 100 oral capsules containing ostarine (enobosarm), a nonsteroidal selective androgen receptor modulator associated with clinical research on lean body mass, androgen receptor signaling, and skeletal muscle physiology.

Biochem Ostarine MK-2866 10mg, 100 cápsulas orales que contienen ostarina (enobosarm), un modulador selectivo no esteroideo del receptor de andrógenos relacionado con investigaciones clínicas sobre masa corporal magra, señalización androgénica y fisiología muscular.